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Although relatively good therapeutic results are achieved in non-advanced cancer, the prognosis of the advanced colon cancer still remains
poor, dependent on local or distant recurrence of the disease.Oneof the factors responsible for recurrence is supposed to be cancer stem
cells (CSCs) or tumor-initiating cells, which are a population of cancer cells with ability to perpetuate themselves through self-renewal
and to generate differentiated cells, thought to be responsible for tumor recurrence. This study globally approach the possible role of
tissue-derived stemcells in the initiation of colon cancer and itsmetastatic process in the liver. Fresh surgical specimens fromcolon cancer,
non-tumor tissue and liver metastasis were obtained directly from the operating room, examined, and immediately processed. CSCs
were selected under serum-free conditions and characterized by CD44 and CD133 expression levels. CD133þ/CD44þ cell populations
were then investigated in parafﬁn-embedded tissues and circulating tumor cells isolated from peripheral blood of the same group of colon
cancer patients. Our data demonstrate that metastatic properties of cell populations from blood and liver metastasis, differently from
primitive tumors, seem to be strictly related to the phenotype CD133 positive and CD44 positive.
J. Cell. Physiol. 228: 408–415, 2013.  2012 Wiley Periodicals, Inc.
Colon cancer is the second leading cause of cancer-related
death. The majority of these deaths are due to metastasis, with
the liver easily the most common site of deposit (LeGolvan and
Resnick, 2010).
Combining surgery and chemotherapy in the treatment of
patients with colon hepatic metastases is increasingly becoming
the standard of care. However, controversy remains regarding
the juxtapositioning of chemotherapy and surgery, the duration
of chemotherapy, and particularly, the use of preoperative
chemotherapy in the treatment of patients with initially
resectable metastases (Nordlinger et al., 2010).
Cancermetastasis has been explained by at least twomodels:
a progression model and an initiating model. In the former,
metastatic capacity is acquired during cancer progression in a
subpopulation of cells through sequential genetic mutations
or epigenetic alterations (Gray, 2010), in genes associated
with proteolysis of local extracellular matrix attachments
(Nagashima et al., 1997), adhesive alterations (Furger et al.,
2001), angiogenesis (Weber, 2008), viable vascular
dissemination, distant embolization, and survival in a new
environment (Folkman, 1990; Hynes, 2003; Bird et al., 2006).
However, not all of these genetic alterations occur during
the process of liver metastasis (Gray, 2010). In the initiation
model, cells with metastatic potential are determined by early
mutational events in a progenitor cell, named cancer stem cell
(CSCs) or tumor-initiating cells (TIC; Clarke and Fuller, 2006;
Polyak and Hahn, 2006; Odoux et al., 2008), even if few data
support the hypothesis of its role in the colon metastatic
process in humans (Horst et al., 2009b; Puglisi et al., 2009;
Ju et al., 2011).
CD44 andCD133 have already been validated as informative
markers of stem cells in both primary tumors and xenografts
(O’Brien et al., 2007; Ricci-Vitiani et al., 2007). CD133,
originally known as AC133, is a glycoprotein also known in
humans and rodents as Prominin 1 (PROM1; Kawamoto et al.,
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2010). It is the founding member of pentaspan transmembrane
glycoproteins (5-transmembrane, 5-TM), whichwas speciﬁcally
regarded as the colon CSC-surface markers. CD133 has been
used to identify and isolate cancer initiating cells from human
colon cancer and it has been demonstrated that CD133þ cells
are able to maintain themselves as well as differentiate and
re-establish tumor heterogeneity upon serial transplantation in
vivo (O’Brien et al., 2007; Ricci-Vitiani et al., 2007). CD44 is a
cell surface glycoprotein involved in cell–cell interactions, cell
adhesion, and migration. It was identiﬁed as the cell-surface
markers of breast cancer and also recently observed to be
related to the distant metastasis of colon cancer (Huang et al.,
2012).
Currently, there are some studies addressing theCD133 and
CD44 co-expression of CSC antigens in colon cancer patients
(Horst et al., 2009a; Salnikov et al., 2009). CD44/CD133
co-expression was signiﬁcantly higher in colon cancers with
early liver metastases compared to those without early liver
metastases and co-expressionwas also associatedwith poorest
prognosis (Huang et al., 2012), suggesting that CD133 and
CD44 proteins co-expression in colon cancer may be a
potential biomarker for early liver metastases. Indeed, Chen
et al. (2011) demonstrated that FACS sorted CD133þ/CD44þ
HCT116 cells are undifferentiated, endowed with extensive
self-renewal and epithelial lineage differentiation capacity in
vitro, more invasive in vitro and responsible solely for liver
metastasis in vivo. However, CD133 and CD44 expression
status and its relation to liver metastasis is still controversial.
A recent study (Hou et al., 2011) showed the critical role of
CD133þ/CD44þ tumor cells in hematogenous metastasis of
liver cancers, underlying that CD133 is responsible for tumor
growth and CD44 is important for invasion; two important
factors in tumor metastasis. Their data also suggest that
CD133þ cells act as TIC-like populations, however were not
necessarily highly invasive, and that CD44 was a marker of
an invasive, but not tumorigenic, sub-population. In addition
to CD133, CD44 has a critical role in tumor metastasis.
Moreover, based on studies of HCC cell lines, CD133þ and
CD44þ were proposed to be markers of TICs in liver cancers
(Zhu et al., 2010). Therefore, CD133 and CD44 could be
regarded asmarkers ofmetastasis-facilitating pathways through
which liver tumor metastasis is jointly promoted.
Therefore, starting from these observations, in this study we
have generated stem cell-enriched human colonosphere
cultures from fresh samples deriving from the same group of
colon cancer and liver metastasis specimens under serum-free
culture conditions, comparing the sphere forming potential
of the clones isolated from the primary culture coming
from both compartments and the differences observed in
the corresponding non-tumor counterpart, adjacent to the
neoplastic lesion. We have established long-term culture
spheres from the three compartments, analyzing the
expression of CD44 and CD133.
Indeed, we have examined colon cancer specimens and
circulating tumor cells (CTC) to investigate the CD133 and
CD44 expression and localization.
Materials and Methods
Patients
Biological tissues for laboratory assays were obtained from
21 patients with a ﬁrst diagnosis of primary colon cancer with
(n¼ 11) or without (n¼ 10) liver metastasis. All patients were
consecutively treated with primary surgery at the Gastrointestinal
Surgery Unit of NCC Bari, Italy. Before undergoing routine
surgery, all patients signed an informed consent authorizing the
Institute to use their removed biological tissues for research
purposes. Routine staging procedures were adopted for disease
staging according to UICC criteria (Greene and Sobin, 2002). Just
after surgical removal of the colon and, if any, of liver metastasis,
tissues were macroscopically analyzed by the pathologist who
performed a sampling from the primary tumor, from adjacent
normal mucosa (located not less than 10 cm from the primary site),
and from liver metastasis. H&E staining conﬁrmed the diagnosis of
colon cancer in all primary and metastatic sites as well the absence
of cancer cells in normal mucosa. About 100mg of tissue without
fat and necrosis was placed in sterile tubes with culture medium
on ice. Patients with liver metastasis were categorized as the
metastatic group (M1); those without liver metastases as the non-
metastatic group (M0).
Isolation and expansion of colon stem cell cultures
After sampling, biological samples were processed as described
previously (Cammareri et al., 2008). The obtained tissue fragments
were washed extensively with PBS and were mechanically
dissociated using scalpels and vigorous trituration to yield small
fragments (<1mm3) and single cells. Enzymatic digestion was
performed using collagenase/hyaluronidase (Stemcell
Technologies, Vancouver, Canada) in DMEM/F12 containing 5mM
Hepes (Sigma, St. Louis, MO) for 2 h at 378C. The suspension was
then ﬁltered through a 100-mm pore size to separate the tissue
fragments from the single cells. The single cell suspension was
cultured in advanced DMEM/F12 (Life Technologies, Monza, Italy)
supplemented with 0.6% BSA (Sigma), 0.6% glucose (Sigma), 2mM
L-glutamine (Euroclone, SPA, Pero, Milano), 9.6mg/ml putrescin
(Sigma), 6.3 ng/ml progesterone (Sigma), 5.2 ng/ml sodium selenite
(Sigma), 25mg/ml insulin (Sigma), 100mg/ml apotransferrin (Sigma),
5mM Hepes (Sigma), 10ml antibiotic–antimycotic (Life
Technologies, Monza, Italy), and 4mg/ml Heparin (Sigma). Growth
factors [20 ng/ml EGF (Peprotech, London, UK) and 10 ng/ml b-
FGF (Peprotech)] were added to the cell culture medium freshly
each week. All cell culture was carried out in non-tissue culture
treated petri at 378C in a 5% CO2 humidiﬁed incubator.
The viable cells were counted using a light microscope by
trypan blue dye exclusion test at day 7. Surviving immature tumor
cells slowly proliferate, and grow as non-adherent spheres. The
formation of such spheres, containing about 50 cells, takes 2
months. Sphere formation was scored as follows: () no sphere
observed; (þ) two spheres per ﬁeld.
Cytospin cell preparation and immunocytochemical staining of
CD44 and CD133
Cells were centrifuged at 800 rpm for 5min, washed with PBS,
and re-suspended in PBS. The cells were attached to coated
microscope slides (Bio Optica, Milano, Italy) in a Cyto-Tek
centrifuge (Sakura Finetek, Alphen Aan Den Rijn, Netherlands) at
2,000 rpm for 10min and dried overnight on a slide warmer at
378C. They were then ﬁxed with acetone and stained. Primary
antibodies speciﬁc for CD133 (Abcam, Cambridge, UK), CD44
(DakoCytomation, Glostrup, Denmark) were used, with
primary antibody binding detected using corresponding Dako
EnVision System-HRP Labelled Polymer secondary antibodies
(DakoCytomation) and AEC Substrate Chromogen
(DakoCytomation). The cells were counterstained with Mayer’s
hematoxylin (DakoCytomation). After incubation, cells were
washed with PBS, and incubated with biotinylated link for 30min,
peroxidase-labeled streptavidin for 30min and 3-amino-9-
ethylcarbazole substrate-chromogen (Labelled Streptavidin-
Biotin2 System-Horseradish Peroxidase; DakoCytomation) for
15min in the dark. After PBS washing, the slides were
counterstained with hematoxylin and mounted with aqueous
mounting medium (DakoCytomation). For negative controls, the
primary antibody was omitted and replaced by PBS.
Photomicrographs of cytospin preparations were acquired
under bright ﬁeld illumination with a Leica DMLB optical
microscope (Leica, Cambridge, UK) and analyzed with Leica
IM1000 software.
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Immunohistochemical staining of CD44 and CD133
Double immunostaining with antibodies for detection of CD44 and
CD133 was performed on parafﬁn-embedded tissue sections and
cytospins, using primary antibodies speciﬁc for CD133 (Abcam),
CD44 (DakoCytomation), and Alexa 488 goat anti-rabbit and
the Alexa 568 goat anti-mouse immunoglobulin G1 secondary
antibodies conjugate (Invitrogen). Tissue sections were then
mounted with aqueous mounting medium (DakoCytomation). For
negative controls, the primary antibody was omitted and replaced
by PBS. Images were obtained on a BX40 microscope (Olympus,
Tokyo, Japan) with a SenSys 1401E Photometrics CCD camera.
Immunohistochemical evaluation
The scoring was performed twice by two persons in a blinded
fashion. CD133 and CD44 staining was detected mainly in the
membrane andwas evaluated as the percentage of immunoreactive
cells with respect to the total analyzed. The result was the mean of
15–20 random ﬁeld at 40 magniﬁcation.
Collection of blood samples
Fifteen milliliters of peripheral blood were collected from each
participant in a vacutainer system with lithium-heparin before
surgery. A written consent should be obtained from all patients
prior to enrolment in the study, and the Ethical Committee of the
NCI approved the protocol which was in accord with the ethical
guidelines of the 1975 Declaration of Helsinki Whole. A control
group found to be healthy from laboratory data was enrolled
among donors (N¼ 30). Their median age was 50 years (range:
40–70 years).
Magnetic labeling
Fifty milliliters of anti-coagulated bloodwere centrifugedwith 400g
for 35min. Buffy coat were collected into 50-ml conical tubes. For
magnetic labeling, the cells were ﬁrst permeabilized using CellPerm
Solution (40ml) from the Carcinoma Cell Enrichment Kit (Miltenyi
Biotec, Bergisch Gladbach, Germany) and incubated for 5min
at room temperature. Fixation was done using 5ml of Cell Fix
Solution for 30min at room temperature. The cells were then
washed twice in dilution buffer. Two hundred microliters of FcR
Blocking Reagent (Miltenyi Biotec) was used for the prevention
of unspeciﬁc binding. Two hundred microliters of anti-cytokeratin
(7/8) Micro Bead was used for magnetic labeling. The magnetic
labeling was performed at room temperature for 45min. Finally,
the cells werewashedonce in cell stain solution and resuspended in
1ml of dilution buffer for magnetic cell separation.
Magnetic separation of cytokeratin 7/8-positive tumor cells
For magnetic separation, the labeled cells were passed through
MSþ (Miltenyi Biotec) separation columns that had been
equilibratedwith dilution buffer. The negative cellswerewashedoff
the column with 3ml of dilution buffer. The retained cells were
eluted from the column outside the magnetic ﬁeld by pipetting 1ml
of dilution buffer onto the column and the cellular suspension was
ﬁltered through a mesh with 30-mm diameter holes.
Immuncytochemical labeling and microscopic analysis
Cells were magnetically separated as described above, and the
enriched cell fraction was spun down on slides using a
cytocentrifuge. Slides were air-dried overnight at room
temperature. Fast Red TR/Naphthol AS-MX Substrate Solution
was added to cell spots for 15min in humidity chamber at 258C.
Slides were then stained with dilute Meyer’s hemalum solution 1:2
in 100mM of Tris–HCl, pH 8.2, washed twice for 1min in double
distilled water, and coverslipped using glycerin plus PBS (1:1).
Results
Tumor tissues of 21 patients with primary colon cancer,
togetherwithmatched adjacent normal tissues, were collected;
11 patients had also liver metastasis. Clinical pathological
characteristics and biological specimens of each patient are
summarized in Table 1. Fresh tissues (Fig. 1A) were processed
and after dissection, viable cells were obtained from 17 out of
18 tumor tissues, 11 out of 18 normal mucosa, and 11 out of 11
livermetastasis (Table 2).We evaluated the growth potential of
these primary cells under serum-free conditions. First
generation of colon spheres (Fig. 1B)were successfully cultured
in 11 out of 17 samples from tumors, in 9 out of 11 from
metastasis and in 6 out of 11 from adjacent normal tissues
(Table 2). To assess whether the ability to form spheres was
maintained during the time of culture, cells were expanded and
after 5months (Table 2) 5 out of 17 samples from tumor tissues,
6 out of 11 from liver metastasis, and 2 out of 11 from non-
TABLE 1. Summary of patient population, tumor sample information, and phenotype characteristics
Sample Age/sex
Tumor
stage Grade
Tumor Liver metastasis Normal tumor adjacent tissue
Vitality Spheres CSCs CD133 CD44 Vitality Spheres CSCs CD133 CD44 Vitality Sphere SCs CD133 CD44
1 66/M T2N0M0 2 þ þ   þ þ þ   
2 70/M T2N0M0 2 þ    þ þ þ   
3 64/M T3N0M0 2 þ    þ 
4 81/F T3N2M0 3 þ    þ þ þ þ  þ
5 68/M T3N0M0 3 þ     þ    
6 68/M T4N2M0 3 þ     þ    
7 62/M T2N0M0 2 þ þ    þ þ   þ
8 42/M T3N1M0 3 þ þ  þ þ þ    þ
9 82/M T4N2M0 3 þ þ þ þ  
10 70/M T3N1M0 3 þ þ þ þ  þ    þ
11 63/F T4N1M1 3 þ þ þ þ þ þ þ þ þ þ þ þ þ  þ
12 52/M T3N2M1 2 þ þ þ þ þ þ þ þ þ þ 
13 87/F T4N2M1 2 þ þ þ þ þ þ þ þ þ þ 
14 73/M T3N2M1 3  þ þ þ þ þ 
15 67/M T4N2M1 2 þ þ  þ þ þ þ þ þ þ þ þ   þ
16 72/M T3N2M1 3 þ þ  þ þ þ þ  þ þ 
17 61/F T3N2M1 2 þ þ  þ þ þ   þ þ 
18 63/F T4N0M1 3 þ   þ þ þ þ  þ þ þ    
19 66/F T4N2M1 3 þ þ   
20 64/F T3N1M1 2 þ   þ þ
21 74/M T3N1M1 3 þ þ þ þ þ
F, female; M, male.
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tumor tissues were able to form spheroids of second and third
generation (Fig. 1C).
The presence of CD44þ cells and CD133þ cells was
evaluated at two isolation steps (Table 2): on the cell
suspensions obtained 1 week after sample processing,
representative of naı¨ve samples (Fig. 2A), and in clones obtained
after 5 months of cell selection (Fig. 3). CD44 was detectable in
13 out of 17 samples from primary tumors, in 6 out of 11 from
normal adjacent mucosa, and in 10 out of 11 from metastasis.
All non-tumor specimens were CD133, whereas 11 out of
17 tumor and 10 out of 11 metastasis samples were CD133þ.
CD133þ cells were signiﬁcantly higher in the tumor
compartment than in the metastatic compartment, and higher
in liver metastasis than in non-tumor tissue (21.6 1.8 vs.
5.4 1.09 vs. 0.56 0.3). The CD44þ cells were signiﬁcantly
higher in the liver metastasis than tumor and non-tumor
compartment (12.6 1.19 vs. 10.7 1.37 vs. 9.18 2.2). Then,
we conﬁrmedCD44 andCD133 expression levels in the clones
obtained after 5 months of cells selection (Fig. 3) and we
found that 100% of the CSCs isolated from the non-tumor
Fig. 1. A:Freshtissuesofprimarycoloncancer(T),matchedadjacentnormaltissues(NT),andlivermetastasis (MET).B:Phasecontrastphotoof
ﬁrst and (C) third generation colon spheres growth under serum-free conditions (40T).
TABLE 2. Summary of patients phenotype and functional characteristics
NT T Liver metastasis
Number 18 18 11
Naive sample
Vitality 11/18 (61%) 17/18 (94.4%) 11/11 (100%)
Expression markers/patients
CD133 0/11 (0%) 11/17 (64.7%) 10/11 (90.9%)
CD44 6/11 (54.5%) 13/17(76.5%) 10/11 (90.9%)
Markers expression mean
%CD133 positive cells 0.56 0.3 21.6 1.8 5.4 1.09
%CD44 positive cells 9.18 2.2 10.7 1.37 12.6 1.19
Sphere production (20 days) 6/11 (54.5%) 11/17 (64.7%) 9/11 (81.8%)
SCs isolated after 5 months cultured 2/11(18.2%) 5/17 (29.4%) 6/11 (54.5%)
SCs phenotype
CD133þ/CD44þ 0 3/5 (60%) 6/6 (100%)
CD133þ/CD44 0 2/5 (40%) 0
CD133/CD44þ 2/2 (100%) 0 0
CD133/CD44 0 0 0
P-e sample
CD133þ/CD44þ cells/patients 0/18 (0%) 9/18 (50%) 10/11 (90.9)
% CD133þ/CD44þ cells 1.3 0.2 13.8 1.1 8.5 0.7
P-e, parafﬁn-embedded; SCs, stem cells.
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compartments were CD133/CD44þ; CSCs isolated from the
tumor compartmentwereCD133þ/CD44þ in 60%of cases and
CD133þ/CD44 in 40%; CSCs from metastasis were all
CD44þ/CD133þ.
We also performed immunoﬂuorescence analysis to
determine the proportion of CD133þ/CD44þ putative
tumorigenic cells within each tumor, scanning for the presence
of the FITC and TRITC staining in the same cell (Fig. 4).
Immunohistochemical staining for CD133 (red, ﬁrst column)
and CD44 (green, second column) showed membrane
localization of the two proteins in epithelial tumor cells
localized at the base of the crypt (Fig. 4B–D), or in tumor cells
scattered throughout the tumor sections (Fig. 4A). Small
number of CD133þ/CD44þ cells were observed only in
primary tumors of patients who develop liver metastasis
(Fig. 4D).Metastasis consists of cancer cells showingmembrane
CD133/CD44 accumulation (Fig. 4E).
We evaluated the difference in the presence of CD44þ/
CD133þ cells and found that are signiﬁcantly higher in the
tumor compartment than in the metastatic once and higher in
liver metastasis than in non-tumor tissue (13.8 1.1 vs.
8.5 0.7 vs. 1.3 0.2).
Fig. 2. CD44 and CD133 expression levels in tumor cells clusters (20T). CD44 and CD133 expression were evaluated. A,B: One week after
samples processing in tumor cells clusters.
Fig. 3. Representative CD44 and CD133 staining in colon spheres growth for 5 months under serum-free conditions.
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When investigating the difference between the tumor
phenotype in the non-metastatic group (10 patients) and the
metastatic group (eight patients), the colocalization analysis
showed more CD133þ/CD44þ cells in the metastatic group
(100%) compared to the non-metastatic group (10%). CD133/
CD44þ cells were detected in 40% of the tumors, while a
complete lack of both proteins was evident in 30% of tumors.
The percentage of CD133þ/CD44þ cells in the primary tumor
and the corresponding liver metastasis in the metastasis group
is presented in Table 3.Wedid not ﬁnd a signiﬁcant difference in
the number of CD133þ/CD44þ cells between the primary
tumors and the corresponding livermetastasis (60.8 27.99 vs.
50.3 16.38; Mann Whitney P value >0.05), suggesting that
they have similar cells of origin.
Peripheral blood from the eight metastatic colorectal cancer
patients was collected and processed as described in methods
and CTCs were isolated. We found in 6 out of 8 detectable
population of CTCs ranging from 20 to 250 per 15ml of blood
(Fig. 5A). CTC retain three different types of cells or cell
clumps, as follows: cytokeratin-positive single-standing tumor
cells (Fig. 5B); cytokeratin-positive cell clumps containing at
least two cells, consisting only of cytokeratin-positive cells
(Fig. 5C); mixed cell clusters containing more than three cells,
with at least one of them cytokeratin-positive (Fig. 5D). In this
Fig. 4. Representative immunohistochemical staining forCD133(red,ﬁrstcolumn)andCD44(green, secondcolumn) inadjacent serial sections
ofhumancoloncancerformalin-ﬁxed,parafﬁn-embeddedspecimensofprimary(A–D)andmetastatic(E)coloncancers.Theprimarytumorswere
CD133R/CD44 (A), CD133/CD44R (B), CD133/CD44 (C), CD133R/CD44R (D), respectively. Small number of CD133R/CD44R cells were
scattered throughout the tumor sections (arrow in D,E). C: CD133/CD44 tumor in which only a speciﬁc signals are visualized.
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study, no cytokeratin-positive cells were found in the blood
of healthy donors. We found 20% of cancer cells showing
membrane CD133/CD44 accumulation; positive cells were not
usually simple, rather they were doublets or clusters. The
CD113þ/CD44þ cells were attached to CD133/CD44 cells;
they appeared either in doublets or in mixed clusters.
Discussion
Cancer stem cell theory has profound implications in terms of
cancer therapy. Indeed, current treatments are hardly able to
completely eradicate cancer cells and are often complicated by
the occurrence of tumor recurrence and/or metastasis. One
hypothesis is that current chemotherapy attacks the bulk of
cancer without affecting stem cells which can re-grow after
treatment, and, eventually, develop the changes responsible for
the occurrence of drug-resistance (Guzman et al., 2002; Guan
et al., 2003; Dean et al., 2005).
Even though the precise contribution of CD133þ/CD44þ
TICs in mediating colon cancer metastasis in human is
contradictory (Shmelkov et al., 2008), recently, it was
demonstrated that CD133þ/CD44þ cells are undifferentiated,
endowed with extensive self-renewal and epithelial lineage
differentiation capacity in vitro, more invasive in vitro and
responsible solely for livermetastasis in vivo (Chen et al., 2011).
In addition, recent evidence suggests that CD133 and CD44
proteins co-expression in colon cancer may be indicative for
early liver metastases (Huang et al., 2011).
To try to shed light on this problem, cells isolated from fresh
tissue specimenswere cultured under non-adherent conditions
to form colon spheres.We found that long-term, non-adherent
culture conditions generate spheres of slowly proliferating
cells; single cells, dissociated from spheres, express both CD44
and CD133. Our data emphasize that the marker CD133 is
higher expressed in primary tumor cells than non-tumor cells
or metastatic cells.We demonstrated the presence of cells also
positive for CD44, in primary colon cancer tissue. 76.5% of
tumor samples and 90.9% of liver metastases expressed CD44,
while only 54.5% of non-tumor samples did. Indeed 64.7% of
tumors and 90.9% of metastasis showed CD133 expression
detectable whereas samples from normal tissues were all
CD133, in agreement with literature data in which it has been
stressed that CD133 expression was extremely infrequent in
normal colon tissues compared to tumor tissues (Fang et al.,
2010), and suggesting that the increased number of CD133
cells in cancer samples maybe a result of their oncogenic
transformation. However, we found that the percentage of
CD133 positive cells was signiﬁcantly higher in the tumor
compartment than in metastatic compartment (21.6 1.8 vs.
5.4 1.09) suggesting that CD133 expression only could be
responsible for tumor growth.While the higher rate of CD44þ
cells in liver metastasis suggests its involvement in tumor
metastasis.
These observations are enforced by those obtained dividing
the non-metastatic patients from the metastatic ones and
observing their tumor phenotype (Table 4): in the metastatic
group all sample CD133þ/CD44þ, while in the non-metastatic
group there was a prevalence of the CD133þ/CD44
phenotype.
CTC are believed to be directly involved in the biology of
the metastatic process and recent observations support the
hypothesis that expression of CD133 in the peripheral blood of
TABLE 3. Percentage of CD133þ/CD44þ cells in the primary tumor and
the corresponding liver metastasis in patients with metastases
Sample Tumor Liver metastasis
11 8.3 36.1
12 64.5 35
16 100 70
14 84 50
15 23.5 43.3
16 60.8 58.3
17 72.2 73.3
18 28.1 47.2
19 73.5 69.2
20 45.6 85.4
21 40 50.3
Median 60.8 50.30
SD DEV 27.99 16.38
Fig. 5. A) Representative CTCs found in peripheral blood from
metastatic colorectal cancer patients. Cells retain three different
types of cells or cell clumps: B) cytokeratin-positive single-standing
tumor cells; C) cytokeratin-positive cell clumps containing at least
two cells, consisting only of cytokeratin-positive cells; D) mixed cell
clusters containing more than three cells, with at least one of them
cytokeratin-positive. E) Representative CTCs processed for
immunoﬂuorescence microscopy as described in the Materials and
Methods. Cells were immunostained with an anti-CD44 mouse
monoclonal antibody (green) and an anti-CD133 rabbit polyclonal
antibody (red).
TABLE 4. Summary of primary tumor phenotype in the non-metastatic
and metastatic group
M0 M1
CD133þ/CD44þ 10% (1/10) 100% (8/8)
CD133/CD44 30% (3/10) 0
CD133þ/CD44 20% (2/10) 0
CD133/CD44þ 40% (4/10) 0
M0, non-metastatic group; M1, metastatic group.
JOURNAL OF CELLULAR PHYSIOLOGY
414 B E L L I Z Z I E T A L .
patients affected with CRC might identify high-risk patients by
detecting putative circulating CSCs that might be responsible
for disease progression after apparently radical surgery (Pilati
et al., 2012). We found detectable population of CTCs in 75%
of metastatic colon cancer patients: 20% of CTCs showed
membrane CD133/CD44þaccumulation; positive cells were
not usually simple, rather they were doublets or clusters. The
CD113þ/CD44þ cells were attached to CD133/CD44 cells;
they appeared either in doublets or in mixed clusters. Our
analysis supports the premises that CTCs represent a sampling
of the phenotypic cell types present in the primary and
metastatic tumor deposits, and the possibility that CTCs
consist of a combination of cells with malignant potential, stem
cell characteristics and actively migrating cells that may go on to
form liver metastatic foci.
Collectively, these results suggest thatCD133þ colon cancer
cells might play an important role in both primary tumors as
well as in metastatic lesions but metastasis of the liver seems to
be strictly related to the phenotype CD133þ and CD44þ. Our
data underline the importance of CD133þ/CD44þ CSCs in
liver metastasis thus warranting further studies on the role(s)
of this subset of cells in the liver metastatic process.
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